← Eichor
Condition: Advanced Unresectable Melanoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Advanced Unresectable Melanoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Mirdametinib in Patients With Advanced NF1-mutant Melanoma
Phase 2 · 1 location(s) · Kevin Kim, MD · NCT07237100Neoadjuvant Tebentafusp for Uveal Melanoma
Phase 2 · 2 location(s) · Thomas Jefferson University · NCT06414590A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
Phase 2 · 12 location(s) · Memorial Sloan Kettering Cancer Center · NCT06594991BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanom
Phase 1 · 2 location(s) · Yana Najjar · NCT04572451A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works
Phase 1/Phase 2 · 11 location(s) · Regeneron Pharmaceuticals · NCT06413680Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07627698A Study of NX-1607 in Adults With Advanced Malignancies
Phase 1 · 17 location(s) · Nurix Therapeutics, Inc. · NCT05107674Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment
Phase N/A · 59 location(s) · Pierre Fabre Pharma GmbH · NCT04045691Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
Phase 2 · 2 location(s) · University of California, San Francisco · NCT04598009A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melan
Phase 3 · 110 location(s) · Regeneron Pharmaceuticals · NCT06246916Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Neg
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT05098210Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untrea
Phase 3 · 81 location(s) · Iovance Biotherapeutics, Inc. · NCT05727904GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
Phase 1/Phase 2 · 4 location(s) · GeneMedicine Co., Ltd. · NCT06265025Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients
Phase N/A · 1 location(s) · University of Wisconsin, Madison · NCT06199713MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
Phase 1/Phase 2 · 13 location(s) · Perspective Therapeutics · NCT05655312Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Loc
Phase 1/Phase 2 · 18 location(s) · Aulos Bioscience, Inc. · NCT05267626A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma
Phase 1/Phase 2 · 1 location(s) · Zhuhai Yufan Biotechnologies Co., Ltd · NCT06727630A Beta-only IL-2 ImmunoTherapY Study
Phase 1/Phase 2 · 27 location(s) · Medicenna Therapeutics, Inc. · NCT05086692A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
Phase 1/Phase 2 · 5 location(s) · Iovance Biotherapeutics, Inc. · NCT06940739Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma
Phase 1/Phase 2 · 1 location(s) · Shanghai JMT-Bio Inc. · NCT07280832A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants W
Phase 1/Phase 2 · 32 location(s) · Marengo Therapeutics, Inc. · NCT05592626Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT05269381Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access an
Phase 2 · 1 location(s) · Mayo Clinic · NCT06265285Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectabl
Phase N/A · 1 location(s) · John Kirkwood · NCT07223411Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With P
Phase 3 · 19 location(s) · mAbxience Research S.L. · NCT07221734AMT-253 in Patients With Advanced Solid Tumours
Phase 1/Phase 2 · 1 location(s) · Multitude Therapeutics Inc. · NCT06209580Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial
Phase 2 · 2 location(s) · Emory University · NCT07155317A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectabl
Phase 2 · 31 location(s) · Innovent Biologics (Suzhou) Co. Ltd. · NCT06797297
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.